Cencora, Inc. COR

Industrials SIC 5122 - Wholesale-Drugs, Proprietaries & Druggists' Sundries NAICS Wholesale Trade › Merchant Wholesalers, Nondurable Goods › Drugs and Druggists' Sundries Merchant Wholesalers derived NYSE

Cencora is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. More specifically, we distribute a comprehensive offering of brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers located in the United States and select global markets, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, medical and dialysis clinics, veterinarians, and other customers. Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related services, including data analytics, outcomes research, reimbursement and pharmaceutical consulting services (including regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance) niche premium logistics services, inventory management, pharmacy automation, pharmacy management, and packaging solutions.

Last close 331.00 2026-10-23
Market cap $63.16B 2026-06-30 share count
52-week range 244.82 - 377.54

Valuation FY2025 figures against the last close

P/S0.2x
P/E41.6x
P/FCF19.7x
EV/EBITDA18.1x
Dividend yield0.7%
Diluted EPS7.96

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $321.33B$293.96B$262.17B$238.59B$213.99B$189.89B$179.59B$167.94B$153.14B$146.85B
Cost of revenue $309.85B$284.05B$253.21B$230.29B$207.05B$184.70B$174.45B$163.33B$148.60B$142.58B
Gross profit $11.48B$9.91B$8.96B$8.30B$6.94B$5.19B$5.14B$4.61B$4.55B$4.27B
SG&A $6.49B$5.66B$5.31B$4.85B$3.59B$2.77B$2.66B$2.46B$2.13B$2.09B
Total operating expenses $6.99B$6.09B$5.72B———————
Operating income $2.63B$2.18B$2.34B$2.37B$2.35B-$5.14B$1.11B$1.44B$1.06B$1.53B
Pre-tax income $2.26B$2.00B$2.16B$2.18B$2.22B-$5.29B$967.1M$1.18B$917.9M$1.39B
Income tax $690.5M$484.7M$428.3M$516.5M$677.3M$1.89B$113.0M$438.5M$553.4M$37.0M
Net income $1.55B$1.51B$1.75B$1.70B$1.54B-$3.41B$855.4M$1.66B$364.5M$1.43B
EPS, basic 8.027.608.628.157.48-16.654.077.611.676.73
EPS, diluted 7.967.538.538.047.39-16.654.047.531.646.32
Shares, diluted (wtd. avg.) 195.2M200.3M204.6M211.2M208.5M204.8M211.8M220.3M221.6M226.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $4.36B$3.13B$2.59B$3.39B$2.55B$4.60B$3.37B$2.49B$2.44B$2.74B
Receivables $25.23B$23.87B$20.91B$18.45B$18.17B$13.85B$12.39B$11.31B$10.30B$9.18B
Inventory $20.49B$19.00B$17.45B$15.56B$15.37B$12.59B$11.06B$11.92B$11.46B$10.72B
Total current assets $52.24B$47.72B$42.80B$39.59B$38.80B$33.06B$28.13B$25.89B$24.30B$22.85B
Property, plant and equipment $2.54B$2.18B$2.14B$2.14B$2.16B$1.48B$1.77B$1.89B$1.80B$1.53B
Goodwill $13.68B$9.32B$9.57B$8.50B$9.03B$6.71B$6.71B$6.66B$6.04B$5.99B
Other intangibles $3.77B$4.00B$4.43B$4.33B$5.26B$1.89B$2.29B$2.95B$2.83B$2.97B
Total assets $76.59B$67.10B$62.56B$56.56B$57.34B$44.27B$39.17B$37.67B$35.32B$33.64B
Accounts payable $54.72B$50.94B$45.84B$40.19B$38.01B$31.71B$28.39B$26.84B$25.40B$23.93B
Short-term debt $117.8M$576.3M$641.3M$1.07B$300.2M$501.3M$139.0M$151.7M$12.1M$610.2M
Total current liabilities $57.82B$54.28B$48.83B$43.48B$41.36B$33.85B$29.58B$27.87B$26.82B$25.28B
Long-term debt $7.54B$3.81B$4.15B$4.63B$6.38B$3.62B$4.03B$400.0M$3.43B$3.58B
Retained earnings $6.53B$5.42B$4.32B$2.98B$1.67B$518.3M$4.24B$3.72B$2.40B$2.30B
Total equity $1.51B$645.9M$666.3M$71.3M$584.4M-$839.6M$2.99B$3.05B$2.06B$2.13B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $3.88B$3.48B$3.91B$2.70B$2.67B$2.21B$2.34B$1.41B$1.50B$3.18B
Depreciation and amortisation $1.05B$1.09B$963.9M$693.9M$505.2M$391.1M$462.4M$465.1M$397.6M$364.7M
Stock-based compensation $148.0M$148.0M$124.6M$93.4M$99.6M$74.4M$58.9M$62.3M$62.2M$65.0M
Capital expenditure $668.0M$487.2M$458.4M$496.3M$438.2M$369.7M$310.2M$336.4M$466.4M$464.6M
Investing cash flow -$4.98B-$618.1M-$2.60B-$368.4M-$6.14B-$379.9M-$375.8M-$1.11B-$498.0M-$3.17B
Financing cash flow $2.25B-$2.33B-$2.22B-$1.75B$1.95B-$603.6M-$1.09B-$242.9M-$1.31B$565.1M
Dividends paid $437.1M$416.2M$398.8M$391.7M$366.6M$343.6M$339.0M$333.0M$320.3M$288.5M
Buybacks $435.5M$1.49B$1.18B$483.7M$82.2M$420.4M$674.0M$639.2M$329.9M$2.27B

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140859-26-000012.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -100B 0 100B 200B 300B 400B Revenue, FY2016: 146.8B Gross profit, FY2016: 4.3B Net income, FY2016: 1.4B Revenue, FY2017: 153.1B Gross profit, FY2017: 4.5B Net income, FY2017: 364.5M Revenue, FY2018: 167.9B Gross profit, FY2018: 4.6B Net income, FY2018: 1.7B Revenue, FY2019: 179.6B Gross profit, FY2019: 5.1B Net income, FY2019: 855.4M Revenue, FY2020: 189.9B Gross profit, FY2020: 5.2B Net income, FY2020: -3.4B Revenue, FY2021: 214B Gross profit, FY2021: 6.9B Net income, FY2021: 1.5B Revenue, FY2022: 238.6B Gross profit, FY2022: 8.3B Net income, FY2022: 1.7B Revenue, FY2023: 262.2B Gross profit, FY2023: 9B Net income, FY2023: 1.7B Revenue, FY2024: 294B Gross profit, FY2024: 9.9B Net income, FY2024: 1.5B Revenue, FY2025: 321.3B Gross profit, FY2025: 11.5B Net income, FY2025: 1.6B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $146.85B $153.14B $167.94B $179.59B $189.89B $213.99B $238.59B $262.17B $293.96B $321.33B
Gross profit $4.27B $4.55B $4.61B $5.14B $5.19B $6.94B $8.30B $8.96B $9.91B $11.48B
Net income $1.43B $364.5M $1.66B $855.4M -$3.41B $1.54B $1.70B $1.75B $1.51B $1.55B

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 5122

TickerCompanyMarket capP/ERevenue growth
MCK MCKESSON CORP $116.68B 26.1x 12.4%
CAH CARDINAL HEALTH INC $58.04B 34.5x 14.2%
HLF HERBALIFE LTD. $1.40B 6.1x 0.9%
NUS NU SKIN ENTERPRISES, INC. $233.2M 1.5x -14.3%
COSM Cosmos Health Inc. $26.3M — 19.9%
HWH HWH International Inc. $20.7M — -30.8%
MEDS DataMeds AI, Inc. $6.8M — 28.7%
HKPD Cellyan Biotechnology Co., Ltd — — —